Tucatinib in Patients With CRC: Data From MOUNTAINEER-01
In the Phase 2 MOUNTAINEER-01 study of patients with HER2-positive metastatic colorectal cancer who were chemo-refractory, the combination of tucatinib and trastuzumab showed an impressive response rate and disease control rate, and median duration of response up to 12 months; Dr. Ahn notes these results compare favorably to prior studies of dual HER2 inhibition, with MOUNTAINEER-01 showing higher response rates.
EP: 1.Overview of Colorectal Cancer (CRC)
EP: 2.Current Treatment Options for CRC
EP: 3.The Role of Biomarker and Molecular Testing in CRC
EP: 4.The Role of HER2 in CRC
EP: 5.Multidisciplinary Care and New Treatment Options in CRC
EP: 6.Case Presentation: A 50-Year-Old Man With Metastatic CRC (mCRC)
EP: 7.Tucatinib in Patients With CRC: Data From MOUNTAINEER-01
EP: 8.Strategies for Adverse Event Management in Patients With CRC Receiving Tucatinib
EP: 9.MOUNAINEER-03: Tucatinib in Combination with Trastuzumab and Chemotherapy in Patients With HER2+ CRC
EP: 10.Case Presentation: A 64-Year-Old Woman With HER2+ mCRC
EP: 11.Trastuzumab Deruxtecan in Patients with HER2+ mCRC: The DESTINY-CRC01 Trial
EP: 12.Managing Interstitial Lung Disease in Patients With HER2+ mCRC Receiving Trastuzumab Deruxtecan
EP: 13.Clinician Insights on the Treatment of Patients With CRC
EP: 14.Future Perspectives and Unmet Needs in HER2+ mCRC Treatment
EP: 15.Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC
EP: 16.A Variety of Treatment Options Are Becoming Available in CRC
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
